These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Neuroleptic-induced reductions in serum dopamine-beta-hydroxylase in schizophrenia. Goodnick PJ; Tong C; Duncavage MB; Meltzer HY Biol Psychiatry; 1983 Dec; 18(12):1485-8. PubMed ID: 6140962 [No Abstract] [Full Text] [Related]
3. Serum dopamine-beta-hydroxylase activity in schizophrenia. Meltzer HY; Nasr SJ; Tong C Biol Psychiatry; 1980 Oct; 15(5):781-8. PubMed ID: 6106516 [TBL] [Abstract][Full Text] [Related]
4. Neuroleptic drug effect on plasma dopamine-beta-hydroxylase in schizophrenia. Baron M; Gruen R; Levitt M; Kane J Neuropsychobiology; 1982; 8(6):312-4. PubMed ID: 6131392 [TBL] [Abstract][Full Text] [Related]
5. Neurochemical studies on tardive dyskinesia. II. Urinary methoxyhydroxyphenylglycol and plasma dopamine-beta-hydroxylase. Markianos M; Tripodianakis J; Garelis E Biol Psychiatry; 1983 Mar; 18(3):347-54. PubMed ID: 6132626 [TBL] [Abstract][Full Text] [Related]
6. Plasma dopamine beta hydroxylase activity in chronic schizophrenic patients tested with single dose of 2-bromo-alpha ergocriptine (Parlodel). Vardi J; Flechter S; Oberman Z; Segal R; Shogan G; Haker O Encephale; 1981; 7(1):95-103. PubMed ID: 7227288 [TBL] [Abstract][Full Text] [Related]
7. Plasma copper and dopamine-beta-hydroxylase in schizophrenia. Baron M; Perlman R; Levitt M; Meltzer H; Gruen R; Asnis L Biol Psychiatry; 1982 Jan; 17(1):115-20. PubMed ID: 7059633 [No Abstract] [Full Text] [Related]
8. [A study of plasma dopamine-beta-hydroxylase activity in patients with schizophrenia]. Kuang PG Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1982 Nov; 15(4):193-7. PubMed ID: 7183426 [No Abstract] [Full Text] [Related]
9. Prolactin levels in schizophrenia: relation to platelet monoamine oxidase, plasma amine oxidase, plasma dopamine-beta-hydroxylase, and erythrocyte catechol-O-methyltransferase activity. Baron M; Levitt M; Asnis L; Fein M Biol Psychiatry; 1983 May; 18(5):579-82. PubMed ID: 6860731 [No Abstract] [Full Text] [Related]
11. Reduced serum dopamine-beta-hydroxylase activity in paranoid schizophrenia. Arató M; Bagdy G; Perényi A Biol Psychiatry; 1982 Jul; 17(7):853-4. PubMed ID: 6126229 [No Abstract] [Full Text] [Related]
12. Biochemical markers in the study of clinical effects and extrapyramidal side effects of neuroleptics. Perényi A; Bagdy G; Arató M; Frecska E Psychiatry Res; 1984 Oct; 13(2):119-27. PubMed ID: 6151713 [TBL] [Abstract][Full Text] [Related]
14. Time course of the antipsychotic effect in schizophrenia and some changes in postmortem brain and their relation to neuroleptic medication. Crow TJ; Cross AJ; Johnstone EC; Longden A; Owen F; Ridley RM Adv Biochem Psychopharmacol; 1980; 24():495-503. PubMed ID: 6105795 [No Abstract] [Full Text] [Related]
15. Plasma DBH activity: relation to genetic factors in schizophrenia. Baron M; Levitt M; Perlman R Commun Psychopharmacol; 1980; 4(3):197-202. PubMed ID: 7226750 [No Abstract] [Full Text] [Related]
16. Neuroleptic drugs and erythrocyte catechol-O-methyltransferase in schizophrenia. Baron M; Gruen R; Levitt M; Kane J Biol Psychiatry; 1982 Nov; 17(11):1339-42. PubMed ID: 6129906 [No Abstract] [Full Text] [Related]